FLX 787

Drug Profile

FLX 787

Alternative Names: FLX-787-ODT; FLX787

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Flex Pharma
  • Class Small molecules
  • Mechanism of Action TRPA1 protein stimulants; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Charcot-Marie-Tooth disease; Multiple sclerosis
  • Phase I Motor neuron disease
  • Preclinical Neuromuscular disorders

Most Recent Events

  • 26 Mar 2018 Adverse events and therapeutic trials data from a phase II trial in Multiple sclerosis released by Flex Pharma
  • 22 Jan 2018 Flex Pharma initiates enrolment in a phase I/II trial for Amyotrophic lateral sclerosis in USA (NCT03334786)
  • 22 Jan 2018 Flex Pharma withdraws phase I/II trial in Amyotrophic lateral sclerosis prior to enrolment, in USA (NCT03338114)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top